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Abstract
Primary Objective: Patients with disorders of consciousness (DOC) face a lack of 
treatments and risk of misdiagnosis, potentially due to motor impairment. Transcranial direct 
current stimulation (tDCS) showed promising results when applied over the prefrontal cortex 
in patients with DOC and over the primary motor cortex (M1) in stroke. The aim of this pilot 
study was to evaluate the behavioral effects of M1 tDCS in patients with DOC. Research 
Design: In this randomized double-blind sham-controlled crossover trial, we included 10 
patients (49±22 years, 7±13 months since injury, 4 unresponsive wakefulness syndrome 
[UWS], 6 minimally conscious sate [MCS], 5 traumatic etiologies). Methods and 
Procedures: One session of tDCS (2 mA for 20 minutes) and one session of sham tDCS 
were applied over M1 in a randomized order with a washout period of minimum 24 hours and 
behavioral effects were assessed using the CRS-R. At the group level, no treatment effect was 
identified on the total score (p=0.55) and on the motor subscale (p=0.75). Two patients 
responded to tDCS by showing a new sign of consciousness (visual pursuit and object 
localization). Conclusions: One session of M1 tDCS failed to improve behavioral 
responsiveness in patients with DOC. Other application strategies should be tested.
Key words: transcranial direct current stimulation (tDCS), disorders of consciousness, motor 
cortex, unresponsive wakefulness syndrome, minimally conscious state. 
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Introduction
Patients with disorders of consciousness (DOC) following severe brain damage represent a 
challenging population regarding diagnosis and treatment. The gold standard for assessing the 
level of consciousness is the Coma Recovery Scale – Revised (CRS-R), that relies on 
behaviors observed at bedside in response to external stimuli (1). It allows to disentangle an 
unresponsive wakefulness syndrome/vegetative state (UWS/VS – state of intermittent 
wakefulness without evidence of awareness of the environment or self (2)) from a minimally 
conscious state (MCS – fluctuating presence of signs of consciousness such as visual pursuit 
or command following (3)). However, the high dependency on motor abilities represent an 
issue for a proportion of clinically unresponsive patients showing partial preservation of 
cortical activity on neuroimaging and/or neurophysiological assessments (4). This specific 
situation, coined MCS*, cognitive-motor dissociation or covert consciousness characterizes 
patients unable to display responses at bedside despite being conscious (4–6). Motor function 
appears, therefore, as one of the key means to increase the patient’s chances of showing signs 
of consciousness and may also allow the use of other behavioral therapies, requiring patients’ 
active participation, to promote recovery. Transcranial direct current stimulation (tDCS), a 
neuromodulation method known to transiently improve the functions of targeted cortical 
areas using non-invasive weak electrical currents (1 – 2 mA) can improve various skills in 
healthy controls and pathological populations (7). When applied on the projection of  the 
primary motor cortex (M1; C3 – C4 according to the 10 – 20 EEG system (8)) in patients 
with stroke, it has shown to induce improvements in hand function, muscle strength or 
activities of daily living, among others (9). In patients with DOC, a single session of tDCS 
over the left dorsolateral prefrontal cortex (DLPFC) can effectively modulate the cortical 
excitability as measured by TMS-EEG (10). From a clinical standpoint, a randomized 
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controlled trial performed on 55 patients showed a significant treatment effect in the 30 
patients in MCS as measured by the CRS-R when one tDCS session was performed over the 
DLPFC for 20 minutes at 2 mA and 43% of the patients in MCS showed a new sign of 
consciousness after the real stimulation that was not present before or after sham however 
these positive behavioral effects were transient (11). Other studies evaluating the effects of 
prefrontal tDCS applied for longer period of time have also shown positive results on 
behavioral improvements (12,13). After these encouraging results and in view of the 
extensive literature for motor cortex stimulation, we conducted a pilot study investigating the 
beneficial effects of one session of M1 tDCS in patients with DOC on their behavioral 
responses as measured by the CRS-R.
Material and Methods
The study was approved by the local ethics committee (CE2009/201). Inclusion criteria 
were : presenting a DOC (UWS/VS or MCS) as established by international guidelines 
(14) and a stable vital condition (no recent event requiring hospitalization, change in 
medication or intubation). Exclusion criteria were the following: documented neurological 
condition prior to the accident; medication comprising sedative agents, Na+ or Ca2+ channel 
blockers or NMDA receptor antagonists, presence of metallic cerebral material, craniectomy 
under the stimulated area (i.e., prefrontal cortex) and uncontrolled epilepsy. Patients received 
one active and one sham session of tDCS in a randomized order with a 1:1 ratio. Direct 
current was applied by a battery-driven current stimulator (DC Stimulator Plus, Neurocare, 
Germany) using saline-soaked surface sponge electrodes (7 x 5 cm). Impedances were always 
kept below 10 kΩ and voltage below 26 V through a built-in safety mode. The active 
electrode (anode) was placed on the area corresponding to C3 or C4 according to the 10-20 
international system for EEG placement (the most affected side was stimulated based on the 
patient’s medical records) while the return electrode (cathode) was placed on the contralateral 
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supraorbital area. During tDCS, the current was increased to 2 mA and applied for 20 
minutes while for the sham condition, the same electrode placement was used but the current 
was applied for 5 seconds and then ramped down. The two tDCS and sham sessions were 
separated by at least 24 hours of washout, which was estimated as a time interval long 
enough (above 90 minutes) for potential tDCS-related effects to disappear (15) and short 
enough for potential spontaneous recovery to not impact the behavioral outcomes. The device 
used offers a built-in blinding mode using anonymous code numbers provided by a third 
party which means both the patient and the investigator were blinded to the treatment 
allocation. Side-effects were collected after each session of tDCS (active and sham) using a 
questionnaire assessing if any of the following signs were observed during or following 
tDCS: redness of the skin, irritation/injury of the skin, signs of pain or discomfort, epileptic 
seizure, increased sleepiness. Behavioral assessments using the CRS-R were performed 
before and after each stimulation sessions by trained clinicians. The CRS-R is a standardized 
behavioral assessment scale consisting of 23 items hierarchically-organized within 6 
subscales interrogating auditory, visual, motor, verbal, communication and arousal functions 
and is the only measurement tool recommended for clinical use in patients with DOC by the 
American Congress of Rehabilitation Medicine with minor reservations (1,16). Our primary 
outcome measure was the tDCS treatment effect computed using a Wilcoxon match-paired 
signed rank-test comparing the differences in CRS-R total score (deltas) as follows: [after 
sham minus before sham] and [after active minus before active]. The statistic Z was used to 
calculate the effect size (ES) r using the formula r=Z/√2n. The treatment effect was 
calculated only in the absence of a carry-over effect that was tested using the same test but 
comparing the CRS-R total scores before active tDCS and before sham tDCS. As a secondary 
outcome, we computed the treatment effect for the motor subscale score. As exploratory 
analyses, we looked at each CRS-R subscale separately using the method described above. 
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We also checked for a potential significant difference between baseline and post CRS-R total 
scores for both active and sham stimulation using a Wilcoxon match-paired signed-rank test. 
We then computed the treatment effect for patients in MCS only (n=6; based on the baseline 
diagnosis) to compare our results to the existing literature. As further explorative analysis, we 
checked for a potential correlation between clinical improvement (i.e., CRS-R total score 
after active tDCS minus total score before active tDCS – delta active tDCS) and time since 
injury using a Spearman’s Correlation test. Statistical analyses were performed using R (17). 
Results were considered significant at p<0.05.
Results
Ten patients were enrolled (4 UWS and 6 MCS; 8 men; 49±22 years; 7±13 months since 
injury; 5 traumatic etiologies, 4 anoxic, 1 stroke – see Table 1). The median [IQR] time 
between the consecutive active and sham tDCS session was 1 [1 – 1.75] days. No side effects 
were observed after the active or the sham session.
INSERT TABLE 1 AROUND HERE
At the group level, no carry-over effect was identified (Z= -1.33; p=0.22) and we did not find 
any significant treatment effect (Z= -0.62; p=0.55; ES=0.10).  Regarding the motor subscale, 
no significant treatment was observed (Z=0.56; p=0.75) neither in any other subscale 
(p>0.05). There was no significant difference in the CRS-R total scores between the baseline 
condition and post stimulation for both active (Z= -1.73; p=0.25) and sham stimulation (Z= -
1.09; p=0.30). For MCS subjects only (n=6), no significant treatment effect was identified 
either (Z= -0.26; p=0.89; ES=0.06). Regarding the influence of time since injury, no 
significant correlation between delta active tDCS and days since injury was identified (t= -
0.291; p=0.778). At the single subject level, one 64-year-old male patient at a subacute stage 
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(28 days post stroke) showed visual pursuit after the active stimulation only, that was not 
observed beforehand or after sham stimulation (only reflexive blinking to threatening 
stimulus) and his diagnosis therefore changed from UWS to MCS. Another patient, 19-year-
old male patient 8 months post traumatic brain injury recovered object localization following 
active stimulation only but his diagnosis remained MCS. No patient changed diagnosis after 
the sham stimulation. 
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Discussion
We aimed to investigate the effects of one session of M1 tDCS on the behavioral responses of 
patients with DOC. As for prefrontal tDCS, M1 tDCS seems to be safe for patients with 
DOC. This aspect still needs to be carefully accounted for since single tDCS-related adverse 
effects, such as skin burn, have been reported in a healthy subject (18).  We did not find any 
significant treatment effect in CRS-R total scores, or in the motor subscale following the 
application of a single session of active tDCS as compared to sham. Beside the small sample 
size, we discuss three potential reasons to explain our results: (i) low dose of tDCS; (ii) 
sensitivity of CRS-R assessment to evaluate motor function in DOC and (iii) possible 
absence of effect of M1 tDCS in DOC. The first possibility is that a single session of tDCS is 
not enough to enhance motor function in patients with DOC. In fact, several studies have 
shown that the number of sessions is one of the most important factors to determine the dose-
effect of tDCS (19,20), but we expected to see at least a transient short-lasting effect. Given 
the extent of neural lesions in DOC, one can assume that several sessions are necessary even 
to observe a short-lasting effect in this population. In addition, the growing literature on tDCS 
in stroke tends to show that tDCS effects are strengthened when combined to behavioral 
therapies (21,22). More intensive protocols combining repeated sessions of M1 tDCS and 
rehabilitation program, such as physical therapy or robotic training, should be tested to 
induce stronger effects on neural plasticity and increase patients’ chances to regain motor-
related signs of consciousness. The second important issue was whether our assessment was 
sensitive enough to detect motor changes. Indeed, we only performed one CRS-R evaluation 
after stimulation while it is known patients with DOC need repeated assessments to obtain an 
accurate behavioral diagnosis because of the important vigilance fluctuations they are subject 
to (23,24). Additionally, other assessments, such as electroencephalography (EEG), 
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electromyography (EMG), or motor evoked potential (MEP) could provide higher sensitivity 
to detect neural changes. These techniques should be implemented in future trials to detect 
subtler changes. Finally, another issue explaining the absence of results could be that patients 
with severe brain injury might require more complex tDCS intervention (e.g., network-based 
stimulation) to be effective. Given the widespread contribution of areas for the planning 
(frontal and prefrontal cortices) and execution of a movement (i.e., basal ganglia, thalamus, 
supplementary motor area, motor and premotor cortices) and the extended lesions observed in 
our population, it may be possible that targeting the motor cortex may not induce as strong 
effects on behavioral signs of consciousness as targeting the prefrontal region. There is 
evidence that when stimulating the left dorsolateral prefrontal cortex (DLPFC) of patients in 
MCS and assessing the behavioral effects with the CRS-R, effect sizes (ES) are greater 
(single stimulation – n=30; ES=0.38 (11); 5 days of stimulation – n=16; ES=0.43 (12)) than 
for posterior parietal cortex stimulation (5 days of stimulation – n= 33; ES=0.31 (25)) or 
motor stimulation in the present study (n=6; ES= 0.06). Therefore, to date, the DLPFC seems 
to be the best candidate of the three (DLPFC, posterior parietal cortex and M1) for applying 
tDCS patients in MCS. This region endorses indeed a lot of executive functions (i.e., 
planning, attention, working memory, decision making and cognitive flexibility). Another 
limitation of this study is that both acute and chronic patients were included; time since injury 
was therefore heterogeneous while acute and chronic patients likely respond differently to 
motor tDCS, given the dramatic progression of the decline in motor function (26,27). 
However, we did not observe a significant impact of time since onset on clinical 
improvement, probably due to the small sample size. Once beyond the proof of concept, 
future studies should be careful to narrow down the time window following injury in their 
inclusion criteria. Despite the absence of a significant treatment effect at the group level, 
relevant clinical results were obtained at the single-subject level. Indeed, one subacute patient 
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(28 days post stroke) with focal lesions in the left basal ganglia and the left insula showed 
visual pursuit only after the active stimulation, which had important clinical implications 
since his diagnosis changed to MCS for the first time. Another chronic patient (8 months post 
traumatic brain injury) with lesions involving the frontal lobes and the hippocampi responded 
to tDCS by showing object localization for the first time after active stimulation. It should be 
noted that the evolution over time of these newly acquired behaviors is unknown. Indeed, no 
further CRS-R data point could be obtained since the patients were discharged from our 
facility afterwards. Nonetheless, for these two responders, applying M1 tDCS has improved 
some oculomotor abilities as measured by the CRS-R visual subscale. Since the parietal 
visual areas and the frontal motor areas are interconnected through cortical and cerebellar 
pathways (28), increasing the excitability of one area using tDCS might propagate to distant 
but connected areas (29). Object localization (i.e., moving a limb toward a presented object) 
also requires a greater participation of motor abilities and stimulating M1 might have directly 
improved these abilities. The identification of these tDCS-responders showing significant 
behavioral improvements remains a key issue. To this end, it is now known that behavioral 
response to tDCS requires at least a partial preservation of the stimulated area both from a 
structural and a metabolic standpoint (30). Therefore, future studies should not only focus on 
the repetition of the sessions but also include patients based on the localization of their 
lesions (e.g., stimulate patients who do not suffer from significant damage in the motor cortex 
but present low scores on the CRS-R motor subscale). Combined therapies (e.g., tDCS and 
motor training) could also be effective  to potentiate tDCS effects (31). 
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Conclusions
M1 tDCS in patients with DOC is safe but failed at improving motor responsiveness at the 
group level. When compared to previous studies, the DLPFC seems to be currently the best 
candidate for enhancing signs of consciousness, especially patients in MCS (11,12,32). 
However, it might be important to further investigate M1 tDCS for DOC. For instance, the 
repetition of sessions, the combination with motor training, or the concurrent stimulation of 
other areas might be interesting future studies.
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Table I: Demographic data, tDCS allocation, CRS-R total scores and main MRI lesions of the the study sample. TSO= Time Since Onset; 
CRS-R= Coma Recovery Scale-Revised; TBI= Traumatic Brain Injury; UWS= Unresponsive Wakefulness Syndrome; MCS= Minimally 
Conscious State
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6a Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 
2b, including how and when they were assessed
4Outcomes
6b Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons n/a
6c If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial n/a
7a Rationale for numbers in the pilot trial /Sample size
7b When applicable, explanation of any interim analyses and stopping guidelines n/a
Randomisation:
8a Method used to generate the random allocation sequence 3-4Sequence 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned
3-4
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Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions
3-4
11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how
3-4Blinding
11b If relevant, description of the similarity of interventions 3-4
Statistical methods 12 Methods used to address each pilot trial objective whether qualitative or quantitative 4
Results
13a For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly 
assigned, received intended treatment, and were assessed for each objective
/Participant flow (a 
diagram is strongly 
recommended) 13b For each group, losses and exclusions after randomisation, together with reasons n/a
14a Dates defining the periods of recruitment and follow-up /Recruitment
14b Why the pilot trial ended or was stopped /
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group See Table I
Numbers analysed 16 For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers




17 For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any
estimates. If relevant, these results should be by randomised group
/
Ancillary analyses 18 Results of any other analyses performed that could be used to inform the future definitive trial 4-5
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 4
19a If relevant, other important unintended consequences n/a
Discussion
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility 6-8
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies 7-8
Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and
considering other relevant evidence
6-8
22a Implications for progression from pilot to future definitive trial, including any proposed amendments 8
Other information
Registration 23 Registration number for pilot trial and name of trial registry n/a
Protocol 24 Where the pilot trial protocol can be accessed, if available n/a
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 8
26 Ethical approval or approval by research review committee, confirmed with reference number 3
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